#United States #Burlington #Azenta Life Sciences #Frenova #Nephronomics

Azenta Life Sciences Teams Up with Frenova

Introduction
In a significant advancement for genomic research in nephrology, Azenta, Inc. has announced its collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics. This partnership is poised to enhance the understanding of cardio-kidney-metabolic diseases through the innovative MyReason® genomics research program, which seeks to leverage technology and data to foster precision medicine for patients globally.

The MyReason Program
The MyReason project is an ambitious initiative designed to explore the genetic mechanisms that contribute to kidney disease. Currently, this program has registered over 35,000 participants who have contributed biospecimens, with goals to expand that number to 50,000 in the upcoming two years. The data collected will serve as a rich resource to better understand kidney-related conditions and develop targeted interventions.

Roles in the Collaboration
Nephronomics, which specializes in Renal Precision Medicine, holds exclusive commercial rights to the MyReason dataset. This dataset serves as the foundation for the Nephronomics Atlas, a comprehensive resource offering in-depth clinical and genomic data concerning cardio-kidney-metabolic diseases. By utilizing advanced artificial intelligence (AI) and machine learning (ML) technologies, Nephronomics can identify novel subtypes of diseases, protective genetic variants, and therapeutic targets necessary for the development of new treatments.

Azenta's contribution to this partnership includes providing genomic sequencing services through its GENEWIZ division and managing long-term sample storage within its expansive global biorepository network. With decades of expertise in multiomics analysis and sample management solutions, Azenta is well-equipped to deliver comprehensive support for complex research endeavors.

Statements from Leadership
Ginger Zhou, President of GENEWIZ, expressed enthusiasm about this collaboration, indicating, "We are thrilled to partner with Frenova and Nephronomics and contribute to the MyReason research program. This collaboration represents a significant step forward in our shared mission to advance precision medicine and improve outcomes for patients."

Jan Walter, President of Frenova, noted, "This large-scale whole genome sequencing initiative marks a pivotal milestone in our journey to build the most comprehensive genotype-phenotype database for patients with CKM diseases. We are equally excited to collaborate with Nephronomics on interrogating the Nephronomics Atlas, promising unprecedented insights that can transform patient care."

James Sietstra, Founder of Nephronomics, added, "Frenova's expertise combined with Azenta's cutting-edge sequencing capabilities are foundational elements of the Nephronomics Atlas. This collaboration is destined to yield groundbreaking insights that will not only advance scientific understanding but also lead to revolutionary therapies and diagnostics in the cardio-kidney-metabolic field."

Company Overviews

• - Nephronomics: A joint venture with Fresenius Medical Care that seeks to establish the world’s largest integrated cardio-kidney-metabolic database featuring over 35,000 patient consents. The Nephronomics Atlas prioritizes deep learning models drawing from extensive clinical data and insights.
• - Frenova: A global Site Management Organization under Fresenius Medical Care that focuses on executing clinical trials in cardio-kidney-metabolic conditions, facilitating streamlined processes and leveraging a vast network of nephrology practices for a more comprehensive reach.
• - Azenta Life Sciences: Known for its life sciences solutions, Azenta aims to accelerate impactful breakthroughs in drug development and clinical research through its reliable sample management and multiomics services, catering to leading pharmaceutical and healthcare institutions.

Conclusion
The collaboration between Azenta, Frenova, and Nephronomics marks a notable step toward unearthing key insights into kidney diseases that impact millions globally. By combining their strengths, these companies are poised to redefine the landscape of precision medicine in nephrology and offer hope for impactful patient outcomes.